Disease-modifying effects of ranibizumab for central retinal vein occlusion

PURPOSE: To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jason M., Khurana, Rahul N., Ghanekar, Avanti, Wang, Pin-wen, Day, Bann-Mo, Blodi, Barbara A., Domalpally, Amitha, Quezada-Ruiz, Carlos, Ip, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Retinal Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850212/
https://www.ncbi.nlm.nih.gov/pubmed/34613454
http://dx.doi.org/10.1007/s00417-021-05224-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850212/
https://www.ncbi.nlm.nih.gov/pubmed/34613454
http://dx.doi.org/10.1007/s00417-021-05224-x

Ejemplares similares